EMBC Stock Overview
A medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Embecta Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.88 |
| 52 Week High | US$21.48 |
| 52 Week Low | US$10.00 |
| Beta | 1.18 |
| 1 Month Change | -5.11% |
| 3 Month Change | -37.34% |
| 1 Year Change | 15.23% |
| 3 Year Change | -60.96% |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Mar 06
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Feb 28Recent updates
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Mar 06Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Feb 28New Initiatives Expected To Make Embecta More Profitable
Dec 04Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Nov 29At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
Nov 07It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Sep 24
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Sep 16 Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
Aug 16Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Aug 14When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
Jul 13Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 12Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15
Feb 21Embecta Corp.'s (NASDAQ:EMBC) Prospects Need A Boost To Lift Shares
Jul 16Embecta Corp. (NASDAQ:EMBC) Shares Could Be 37% Below Their Intrinsic Value Estimate
Mar 30Embecta Corp. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 17Shareholder Returns
| EMBC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.8% | 4.1% | 4.7% |
| 1Y | 15.2% | 6.5% | 7.7% |
Return vs Industry: EMBC exceeded the US Medical Equipment industry which returned 6.5% over the past year.
Return vs Market: EMBC exceeded the US Market which returned 7.9% over the past year.
Price Volatility
| EMBC volatility | |
|---|---|
| EMBC Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: EMBC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EMBC's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 2,100 | Dev Kurdikar | www.embecta.com |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors.
Embecta Corp. Fundamentals Summary
| EMBC fundamental statistics | |
|---|---|
| Market cap | US$683.08m |
| Earnings (TTM) | US$58.20m |
| Revenue (TTM) | US$1.11b |
11.9x
P/E Ratio0.6x
P/S RatioIs EMBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBC income statement (TTM) | |
|---|---|
| Revenue | US$1.11b |
| Cost of Revenue | US$395.10m |
| Gross Profit | US$712.60m |
| Other Expenses | US$654.40m |
| Earnings | US$58.20m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 09, 2025
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 64.33% |
| Net Profit Margin | 5.25% |
| Debt/Equity Ratio | -200.9% |
How did EMBC perform over the long term?
See historical performance and comparisonDividends
5.1%
Current Dividend Yield60%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/25 12:16 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Embecta Corp. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |